<DOC>
	<DOCNO>NCT02748057</DOCNO>
	<brief_summary>The study assess safety tolerability MK-0653H ( Ezetimibe 10 mg+ Rosuvastatin 2.5 mg ) MK-0653H ( Ezetimibe 10 mg+ Rosuvastatin 5.0 mg ) 52 week Japanese participant hypercholesterolemia uncontrolled monotherapy Ezetimibe 10 mg Rosuvastatin 5 mg .</brief_summary>
	<brief_title>A Clinical Trial Assess Long Term Safety Tolerability MK-0653H Japanese Participants With Hypercholesterolemia ( MK-0653H-833 )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Japanese Outpatient hypercholesterolemia Female participant reproductive potential agree remain abstinent use ( partner use ) two acceptable method birth control date sign informed consent 14 day last dose study drug Will maintain stable diet consistent Japan Atherosclerosis Society Guideline 2012 ( JAS 2012 ) prevention atherosclerotic cardiovascular disease duration study Uncontrolled hypertension ( treat untreated ) Uncontrolled type 1 type 2 diabetes mellitus Homozygous Familial Hypercholesterolemia undergone lowdensity lipoprotein ( LDL ) apheresis Uncontrolled endocrine metabolic disease know influence serum lipid lipoproteins Has gastrointestinal tract bypass , significant intestinal malabsorption History cancer within past 5 year ( except successfully treat dermatological basal cell squamous cell carcinoma situ cervical cancer ) Human Immunodeficiency Virus ( HIV ) positive History drug/ alcohol abuse within past 5 year psychiatric illness adequately control stable pharmacotherapy Consumes 25 g alcohol per day Currently follow excessive weight reduction diet Currently engage vigorous exercise regimen ( e.g . ; marathon training , body build train etc . ) intend start training study Hypersensitivity intolerance Ezetimibe Rosuvastatin Myopathy rhabdomyolysis Ezetimibe statin Pregnant lactating Taking investigational drug and/or take investigational drug within 30 day</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>